BetaEntity Annotation Prototype
← Back to institutions

Annotated abstract

4CPS-197 Persistence and adherence to integrase inhibitors-based antiretroviral treatment in naïve-HIV patients

ejhpharm · 2026-03-18 · canonical JSON source

20 visible annotations · policy: published · automated confidence ≥ 75.00%

Document resource

Background and Importance The aim of antiretroviral therapy (ART) is to supress HIV replication, thereby reducing the risk of opportunistic infections and preventing transmission. Pharmacists play a key role in patient education, adherence support and monitoring treatment effectiveness and tolerance.Aim and Objectives To evaluate persistence and adherence to ART based on integrase inhibitors in HIV-naïve patients at 6 and 12 months. Additionally, the study aims to evaluate reasons for discontinuation and adverse events (AEs).Material and Methods This was an observational and retrospective study conducted in a tertiary hospital with a multidisciplinary team including clinical pharmacists involved in the follow-up of HIV patients. We included patients who were diagnosed with HIV infection between 08/2022-07/2024 and who started integrase inhibitors-based ART. Data were collected from clinical records and pharmacy claims. Patients who moved to another healthcare centre within the first year of follow-up were excluded. To determine medication adherence, we measured the proportion of days covered (PDC), where a threshold ≥90% is used to identify optimal adherence to ART according to Pharmacy Quality Alliance.Results We identified 69 naïve patients who started ART treatment. At 6 months, 95.7% (n=66) remained on the initial ART regimen, while one patient required an ART switch due to drug resistance and two were lost to follow-up. At 12 months, 87.0% (n=60) were persistent to initial regimen, while four patients switched to long-acting regimens, one discontinued due to AE, and one was lost to follow-up. The mean adherence at 6 and 12 months was 97.5% and 96.4%, respectively. A 90.9% and 95.0% of patients achieved a threshold of ≥90% PDC at 6 and 12 months, respectively. At 6 months, 71.2% (47/63) had undetectable viremia and 88.7% (55/62) had a CD4 lymphocyte count ≥200 cells/mm 3. At 12 months, these results were 85.5% (47/55) and 92.9% (52/56), respectively.Conclusion and Relevance Our cohort of HIV-naïve patients showed high levels of persistence and adherence to integrase inhibitor-based ART during their first year. These findings show the effectiveness and tolerability in naïve patients in real-world conditions. They also suggest the benefits of follow-up by a multidisciplinary team.Conflict of Interest No conflict of interest